SCPS (Scopus BioPharma) Total Stockholders Equity: $-9.45 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Scopus BioPharma Total Stockholders Equity?

Scopus BioPharma SCPS Total Stockholders Equity is $-9.45 Mil as of Jun. 2023.

Scopus BioPharma's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-9.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Scopus BioPharma's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Scopus BioPharma's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.00.

Scopus BioPharma  (OTCPK:SCPS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Scopus BioPharma's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-9.452-0)/42.084
=-0.22

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Scopus BioPharma's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -9.452
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Total Stockholders Equity Related Terms

Scopus BioPharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Total Stockholders Equity Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial -0.01 -0.08 -1.83 4.02 -6.56

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.70 -5.50 -6.56 -6.95 -9.45
What does a Total Stockholders Equity of $-9.45 Mil mean?
Scopus BioPharma (SCPS) has a Total Stockholders Equity of $-9.45 Mil as of Jun. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scopus BioPharma and its competitors.
Is Scopus BioPharma's Total Stockholders Equity too high?
Scopus BioPharma's current Total Stockholders Equity is $-9.45 Mil.
How does Scopus BioPharma's Total Stockholders Equity compare to AMPE and DRMA?
Scopus BioPharma's Total Stockholders Equity of $-9.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scopus BioPharma and its competitors. Scopus BioPharma's current Total Stockholders Equity is $-9.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Total Stockholders Equity of $-9.45 Mil. The current Total Stockholders Equity is $-9.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Total Stockholders Equity is $-9.45 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.